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BACKGROUND & AIMS: The interferon-free regimen of ABT-
450 (a protease inhibitor), ritonavir, ombitasvir (an NS5A
inhibitor), dasabuvir (a non-nucleoside polymerase inhibi-
tor), and ribavirin has shown efﬁcacy in patients with
hepatitis C virus (HCV) genotype 1b infection—the most
prevalent subgenotype worldwide. We evaluated whether
ribavirin is necessary for ABT-450, ritonavir, ombitasvir,
and dasabuvir to produce high rates of sustained virologic
response (SVR) in these patients. METHODS: We performed
a multicenter, open-label, phase 3 trial of 179 patients with
HCV genotype 1b infection, without cirrhosis, previously
treated with peginterferon and ribavirin. Patients were
assigned randomly (1:1) to groups given ABT-450, ritonavir,
ombitasvir, and dasabuvir, with ribavirin (group 1) or
without (group 2) for 12 weeks. The primary end point was
SVR 12 weeks after treatment (SVR12). We assessed
the noninferiority of this regimen to the rate of response
reported (64%) for a similar population treated with
telaprevir, peginterferon, and ribavirin. RESULTS: Groups
1 and 2 each had high rates of SVR12, which were non-
inferior to the reported rate of response to the combination
of telaprevir, peginterferon, and ribavirin (group 1: 96.6%;
95% conﬁdence interval, 92.8%–100%; and group 2: 100%;
95% conﬁdence interval, 95.9%–100%). The rate of
response in group 2 was noninferior to that of group 1. No
virologic failure occurred during the study. Two patients
(1.1%) discontinued the study owing to adverse events,
both in group 1. The most common adverse events in groups
1 and 2 were fatigue (31.9% vs 15.8%) and headache
(24.2% vs 23.2%), respectively. Decreases in hemoglobin
level to less than the lower limit of normal were more
frequent in group 1 (42.0% vs 5.5% in group 2; P < .001),
although only 2 patients had hemoglobin levels less than 10
g/dL. CONCLUSIONS: The interferon-free regimen of ABT-
450, ritonavir, ombitasvir, and dasabuvir, with or without
ribavirin, produces a high rate of SVR12 in treatment-
experienced patients with HCV genotype 1b infection. Bothregimens are well tolerated, as shown by the low rate of
discontinuations and generally mild adverse events.
ClinicalTrials.gov number: NCT01674725
Keywords: PEARL-II; Ribavirin-Free; IFN; Interferon-Free
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Watch this article’s video abstract and others at http://tiny.cc/j026c.Scan the quick response (QR) code to the left
with your mobile device to watch this article’s
video abstract and others. Don’t have a QR code
reader? Get one by searching ‘QR Scanner’ in
your mobile device’s app store.ntreated chronic hepatitis C virus (HCV) infection isUa leading cause of liver damage, cirrhosis, and he-
patocellular carcinoma.1 The prevalence of HCV infection is
estimated to be 3% worldwide and results in approximately
350, 000 deaths annually.2,3 Genotype 1 accounts for ap-
proximately 70% of all HCV infections and subgenotype 1b is
most predominant in Europe and Eastern Asia. Approved
direct-acting antiviral agents (DAAs), telaprevir, boceprevir,
sofosbuvir, and simeprevir, given with peginterferon
(pegIFN) and ribavirin (RBV), have reported sustained viro-
logic response (SVR) rates of 67%–89% in HCV genotype
1–infected patients. Response rates with DAA regimens are
generally lower in patients who have failed previous pegIFN-
containing treatment regimens than in treatment-naive
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LIVERpatients, and are noticeably lower among prior null
responders.4–8 In addition, the toxicity of pegIFN and long
duration of therapy (up to 48 weeks with some regimens)
are a hardship for patients.9 Notably, pegIFN-based treat-
ment regimens have well-documented adverse event (AE)
proﬁles including inﬂuenza-like symptoms and depression,
which have led to unfavorable discontinuation rates in clin-
ical trials,6,9–12 and RBV also has associated side effects
including teratogenicity, hemolytic anemia, and rash.13,14
All-oral and interferon-free HCV treatment regimens
with DAAs provide wider treatment access to patients in
need with chronic liver disease. ABT-450 is an NS3/4A
protease inhibitor with in vitro nanomolar antiviral activity
and is co-dosed with the CYP3A4 inhibitor, ritonavir, which
signiﬁcantly increases peak and trough drug concentrations,
enabling once-daily dosing.15 The multitargeted, all-oral
combination of the 3 DAAs of ABT-450/ritonavir, ombi-
tasvir (formerly ABT-267), an HCV NS5A inhibitor with
pangenotypic picomolar antiviral activity,16 and dasabuvir
(formerly ABT-333), an HCV NS5B RNA non-nucleoside
polymerase inhibitor, with RBV was shown in a phase 2b
trial to achieve high rates of SVR 12 weeks post-treatment
(SVR12) in treatment-naive and treatment-experienced ge-
notype 1–infected patients. With this regimen, a 93% SVR12
rate was achieved in genotype 1–infected noncirrhotic pa-
tients with prior null response to pegIFN/RBV, and a 100%
SVR12 rate was achieved in the genotype 1b patient sub-
set.17 These high response rates in prior null responders,
considered difﬁcult to cure, are promising and require
conﬁrmation in a large phase 3 trial. Although ABT-450/
ritonavir/ombitasvir and dasabuvir with RBV may achieve
high SVR12 rates, determining the beneﬁt gained by
including RBV in the regimen has not been assessed in these
patients. This phase 3 study (PEARL-II) evaluated the efﬁ-
cacy and safety of 12 weeks of treatment with coformulated
ABT-450/ritonavir/ombitasvir and dasabuvir with or
without RBV exclusively in noncirrhotic pegIFN/RBV
treatment-experienced HCV genotype 1b–infected patients.
Materials and Methods
Patients
Adults were age 18–70 years at the time of screening from
43 sites in Austria, Belgium, Italy, The Netherlands, Portugal,
Puerto Rico, Sweden, Switzerland, Turkey, and the United States.
Patients were required to have documentation that they previ-
ously failed treatment with pegIFN/RBV. Eligible patients were
required to be noncirrhotic with chronic HCV genotype 1b
infection for at least 6 months with an HCV-RNA level greater
than 10, 000 IU/mL at screening. Patients were excluded if they
had evidence of co-infection with any HCV genotype other than
1b or tested positive for hepatitis B surface antigen or anti-
–human immunodeﬁciency virus antibody at screening. Detailed
eligibility criteria are provided in the Supplementary Appendix.
Study Design
Patients were stratiﬁed by type of previous nonresponse to
pegIFN/RBV treatment (null responders, partial responders,
and relapsers) and randomized 1:1 to receive the 12-weekregimen of coformulated ABT-450/ritonavir/ombitasvir (150/
100/25 mg once daily) and dasabuvir (250 mg twice daily)
with either weight-based RBV dosed twice daily (1000 mg daily
if body weight < 75 kg, 1200 mg daily if body weight was  75
kg) for group 1 or without RBV for group 2 (Supplementary
Figure 1). After 12 weeks of treatment, patients were fol-
lowed up for an 48 additional weeks. Additional details on
study design are in the Supplementary Appendix.
The study was conducted in accordance with the Interna-
tional Conference of Harmonisation guidelines, applicable reg-
ulations, and guidelines governing clinical study conduct and
ethical principles that have their origin in the Declaration of
Helsinki. All patients provided written informed consent. All
authors had access to relevant data, and critically reviewed,
revised, and approved the manuscript.
Safety Assessments
Adverse event assessments were reported from the time of
study drug administration until 30 days after the last dose and
were judged as mild, moderate, or severe; clinical laboratory
testing was performed at each study visit. Serious AEs were
recorded throughout the study.
Efﬁcacy End Points
Plasma samples were collected at screening and at each
study visit and HCV-RNA levels were determined using the
Roche COBAS TaqMan real-time reverse-transcription poly-
merase chain reaction assay v2.0 (Roche Molecular Diagnostics,
Pleasanton, CA) at a central laboratory. A ﬁxed-sequence
testing procedure was used to control type I error at 0.05.
The primary efﬁcacy end point was noninferiority of the SVR12
rates (assessed by HCV-RNA level < 25 IU/mL) in group 2 and
group 1 to the historical SVR12 rate for telaprevir plus pegIFN/
RBV in HCV genotype 1b–infected patients who were relapsers,
partial responders, or null responders to previous pegIFN/RBV
treatment,4 adjusted for noncirrhotic patients in this study.
Group 1 and group 2 noninferiority could be claimed if the
SVR12 lower limit of the 95% conﬁdence interval (CI) was
greater than the upper limit of the CI for the historical rate
minus a 10.5% noninferiority margin (64%). Further details of
historical noninferiority calculations are provided in the
Supplementary Appendix. Secondary efﬁcacy end points in the
ﬁxed sequence included the following: (1) comparison of the
percentage of patients with a decrease in hemoglobin level to
less than the lower limit of normal at the end of treatment; (2)
superiority of group 1 and group 2 to the historical rate for
telaprevir plus pegIFN/RBV (75%); and (3) noninferiority of
group 2 to group 1 using a 10.5% noninferiority margin for the
SVR12 difference. The percentage of patients with on-treatment
virologic failure and post-treatment relapse also was assessed.
Virologic Failure Criteria
Virologic failure leading to discontinuation of study drug
was determined if the following criteria occurred: conﬁrmed
increase from nadir in HCV-RNA level (deﬁned as 2 consecutive
HCV-RNA measurements greater than 1 log10 IU/mL greater
than nadir) at any point during treatment; failure to achieve
HCV-RNA level less than 25 IU/mL by week 6; and conﬁrmed
HCV-RNA level of 25 IU/mL or greater in 2 consecutive mea-
surements at any point during treatment after HCV-RNA level
Table 1.Baseline Demographics and Characteristics, n (%)
Parameter
Group 1
3D þ RBV
(N ¼ 91)
Group 2
3D
(N ¼ 95)
Sex, male 45 (49.5) 57 (60.0)
Race
White 84 (92.3) 86 (90.5)
Black 3 (3.3) 6 (6.3)
Ethnicity, Hispanic/Latino 4 (4.4) 2 (2.1)
Geographic region
North America 14 (15.4) 19 (20.0)
Europe 77 (84.6) 76 (80.0)
Mean age, y (SD) 54.2  10.9 54.2  10.5
Mean BMI, kg/m2 (SD) 26.2  4.1 27.5  4.3
IL28B genotype
CC 10 (11.0) 7 (7.4)
Non-CC 81 (89.0) 88 (92.6)
Mean HCV-RNA level,
log10 IU/mL (SD)
6.56  0.56 6.48  0.53
Previous pegIFN/RBV nonresponse
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Rwas less than 25 IU/mL. Post-treatment relapse was conﬁrmed
in patients with HCV-RNA level less than 25 IU/mL at the end of
treatment and subsequent HCV-RNA level of 25 IU/mL or
greater in 2 consecutive measurements.
Statistical Analyses
Efﬁcacy analyses were performed using the intent-to-treat
population, deﬁned as all randomized HCV genotype
1b–infected patients who received at least one dose of cofor-
mulated ABT-450/ritonavir/ombitasvir. The safety population
included all patients who received at least one dose of study
drug. A population of 90 patients per treatment arm was
calculated to provide greater than 90% power to achieve
noninferiority of the active regimen to the historical threshold
(64%).
SAS software (SAS Institute, Inc, Cary, NC) for the UNIX
operating system was used for all analyses. All statistical tests
and all conﬁdence intervals were 2-sided with a signiﬁcance
level of .05.Null responder 32 (35.2) 33 (34.7)
Partial responder 26 (28.6) 27 (28.4)
Relapser 33 (36.3) 35 (36.8)
Baseline ﬁbrosis stage
F0–F1 64 (70.3) 61 (64.2)
F2 13 (14.3) 21 (22.1)
F3 14 (15.4) 13 (13.7)
NOTE. Fibrosis scoring information is provided in the
Supplementary Appendix.
BMI, body mass index; IL, interleukin; 3D, 3 direct-acting
antivirals.Results
Baseline Patient Demographics
and Characteristics
Patient screening began on August 14, 2012, and the
ﬁnal SVR12 data were collected on January 16, 2014. Of
324 patients screened, 187 were randomized and 186
received study drug (91 in group 1, 95 in group 2)
(Supplementary Consort Flow Chart). Null responders,
partial responders, and relapsers to previous pegIFN/RBV
treatment comprised 34.9%, 28.5%, and 36.6% of the study
population, respectively, evenly stratiﬁed between treat-
ment arms (Table 1). Reasons for screen failures are pro-
vided in the Supplementary Appendix. Seven randomized
patients, 3 in group 1 and 4 in group 2, were not included in
the intent-to-treat efﬁcacy population. Of these, 6 patients
were enrolled before a protocol amendment and received
noncoformulated ABT-450/ritonavir/ombitasvir, 3 of whom
were genotype 1a; a seventh patient’s HCV subgenotype was
not determined.
Efﬁcacy
After 12 weeks of treatment, 96.6% (85 of 88; 95% CI,
92.8–100) of group 1 and 100% (91 of 91; 95% CI,
95.9–100) of group 2 patients achieved SVR12 using the
intent-to-treat population for both groups (Figure 1;
Table 2, Supplementary Figure 2). For the primary end
point, SVR12 rates in both treatment groups were non-
inferior to the historical SVR rate for telaprevir plus pegIFN/
RBV in comparable treatment-experienced patients. Both
treatment groups also were superior to the historical rate.
Noninferiority of group 2 to group 1 was shown because
the treatment difference in SVR12 rates was 3.4% (95% CI,
-0.4 to 7.2).
No patients from either treatment group experienced
on-treatment virologic failure or post-treatment relapse.
Of the 3 patients in group 1 who did not achieve SVR12,
there were 2 (2.3%) patients who discontinued study drugbecause of AEs, and 1 patient was lost to follow-up evalu-
ation after SVR4 (Table 3).
Sustained virologic responses in both groups were not
inﬂuenced by previous nonresponse, age, race, or inter-
leukin 28B genotype. Among group 1 null responders, par-
tial responders, and relapsers to previous pegIFN/RBV
treatment, SVR12 rates were 93.5%, 96.0%, and 100%,
respectively. Group 1 rates were similarly high regardless of
interleukin 28B genotype (CC, 100%; CT, 96.4%; and TT,
95.5%), or sex (male, 95.3%; female, 97.8%). Group 2
SVR12 rates were 100% in all subgroups.
Finally, the 7 patients excluded from the efﬁcacy subset
because they received noncoformulated study drug,
conﬁrmed genotype 1a, or undetermined genotype, all
completed treatment and achieved SVR12.
Safety
Treatment-emergent AEs (TEAE) were experienced by
79.1% of patients in group 1 and by 77.9% of patients in
group 2. Most TEAEs were mild, with the most commonly
reported events in group 1 and group 2 being fatigue (31.9%
vs 15.8%; P¼ .015), headache (24.2% vs 23.2%; P¼NS), and
nausea (20.9% vs 6.3%; P ¼ .005), respectively (Table 3).
Patients in group 1 also experienced statistically signiﬁcantly
more events of insomnia, anemia, rash, and increased blood
bilirubin levels, all known to be associated with RBV use; no
patient discontinued study drug because of these events.
Table 2. Intent-to-Treat Virologic Response
Parameter
Group 1
3D þ RBV, n/N (%)
Group 2
3D, n/N (%)
Treatment difference
(95% CI)
SVR12 85/88 (96.6) 91/91 (100) 3.4 (0.4 to 7.2)
Previous nonresponse
Null responder 29/31 (93.5) 32/32 (100) 6.5 (2.2 to 15.1)
Nonresponder/partial responder 24/25 (96.0) 26/26 (100) 4.0 (3.7 to 11.7)
Relapser 32/32 (100) 33/33 (100) 0 (N/A)
Sex
Male 41/43 (95.3) 54/54 (100) 4.7 (1.6 to 10.9)
Female 44/45 (97.8) 37/37 (100) 2.2 (2.1 to 6.5)
Race
Black 3/3 (100) 5/5 (100) 0 (N/A)
Non-black 82/85 (96.5) 86/86 (100) 3.5 (0.4 to 7.5)
IL28B genotype
CC 10/10 (100) 7/7 (100) 0 (N/A)
CT 54/56 (96.4) 64/64 (100) 3.6 (1.3 to 8.4)
TT 21/22 (95.5) 20/20 (100) 4.5 (4.2 to 13.2)
NOTE. The intent-to-treat genotype 1b efﬁcacy population includes all patients with subgenotype 1b infection who were
assigned to and treated with ABT-450/ritonavir/ombitasvir co-formulated drug.
IL, interleukin; N/A, not applicable; 3D, three direct-acting antivirals.
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because of AEs, both in group 1. One patient experienced 2
serious AEs of pancreatitis that were considered by the
investigator not to be study drug–related. This patient had
increased amylase levels on day 1 before receiving study
drug; on day 11, the patient reported abdominal pain and
was hospitalized on day 13, at which point study drugs were
discontinued. The patient experienced another mild episode
of pancreatitis on day 31 that resolved by day 36. This pa-
tient had an HCV-RNA level of 28 IU/mL on day 8. Resis-
tance analysis performed on baseline and post-treatment
samples showed no NS3 or NS5B resistance-associated
variants present at baseline. The NS5A R30Q variant wasFigure 1. ITT genotype 1b efﬁcacy subset treatment
response over time. Percentage of patients achieving viro-
logic response (95% CIs) are presented for week 4 of
treatment (RVR), end of treatment (EOTR), 4 weeks post-
treatment (SVR4), and SVR12, as well as n/N within the
bars graphs.present at baseline, and R30Q and Y93H were present at
post-treatment week 12. Another patient reported anxiety,
tachycardia, fever, and dyspnea on day 36 that led to study
discontinuation; HCV-RNA level on day 32 before discon-
tinuation was less than 15 IU/mL. This patient had no
resistance-associated variants in NS3 or NS5A at baseline;
NS5B variants C316N and S556G were present at baseline
and post-treatment week 4. Excluding the event
of pancreatitis, 3 other serious TEAEs (cellulitis, neph-
rolithiasis, and osteoarthritis) were reported; none were
judged to be study drug–related or led to study drug
discontinuation.
Hemoglobin levels less than the lower limit of normal at
the end of treatment, a secondary end point, was experi-
enced more often by patients in group 1 compared with
patients in group 2 (42.0% vs 5.5%, respectively; P < .001),
although clinically signiﬁcant grade 2 hemoglobin level
declines to less than 10 g/dL at the end of treatment
occurred in only 2 (1.1%) patients, both in group 1. No
patient required a blood transfusion or erythropoietin.
Increases in total bilirubin level greater than 2 times the
upper limit of normal (ULN) were reported in 15.4% of
patients in group 1 and in 1.1% of patients in group 2
(P < .001), with 8.8% of patients in group 1 and 0% in
group 2 reporting greater than 3 times the ULN. Mean levels
of total bilirubin peaked at week 1 (predominantly indirect
bilirubin) and were reduced at week 2 in both groups,
although levels remained increased throughout the treat-
ment period only in group 1 (Supplementary Figure 3). The
mean total bilirubin level at week 1 was 1.6 mg/dL in group
1 and 0.9 mg/dL in group 2; by week 2, the mean levels
were reduced to 1.2 and 0.7 mg/dL, respectively. Five
(5.5%) patients in group 1 and 2 (2.1%) patients in group 2
reported hyperbilirubinemia; 3 (3.3%) patients in group 1
reported jaundice. One hyperbilirubinemia and 1 jaundice
event were moderate in severity and the remaining events
Table 3.Patients Reporting TEAEs
Parameter
Group 1
3D þ RBV, n (%)
(N ¼ 91)
Group 2
3D, n (%)
(N ¼ 95) P value
Any TEAE 72 (79.1) 74 (77.9)
Any severe TEAE 0 (0) 1 (1.1)
Any serious TEAE 2 (2.2) 2 (2.1)
TEAE leading to discontinuation 2 (2.2) 0 (0)
Common TEAEsa
Fatigue 29 (31.9) 15 (15.8) .015
Headache 22 (24.2) 22 (23.2)
Nausea 19 (20.9) 6 (6.3) .005
Insomnia 13 (14.3) 3 (3.2) .008
Pruritus 13 (14.3) 8 (8.4)
Diarrhea 12 (13.2) 12 (12.6)
Asthenia 11 (12.1) 7 (7.4)
Anemia 10 (11.0) 0 (0) <.001
Blood bilirubin level increased 8 (8.8) 0 (0) .003
Rash 8 (8.8) 1 (1.1) .017
Chemistry and hematologic values of interest during treatment
Hemoglobin level < LLN at end of treatmentb 37 (42.0) 5 (5.5) <.001
Total bilirubin level > 3 ULN 8 (8.8) 0 (0) .003
ALT level > 5 ULN 0 (0) 0 (0)
AST level > 5 ULN 0 (0) 1 (1.1)
LLN, lower limit of normal; ULN, upper limit of normal; 3D, three direct-acting antivirals.
aInvestigator-reported TEAEs present in  10% of either treatment group or with a statistically signiﬁcant difference between
treatment groups.
bN ¼ 88 and 91 for group 1 and group 2, respectively, using the intent-to-treat genotype 1b efﬁcacy population.
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Ribavirin dose modiﬁcation occurred in 5 patients, 3 owing
to anemia, 1 owing to hyperbilirubinemia, and 1 was dose
adjusted owing to a decrease in weight; all achieved SVR12.
The percentage of patients with postbaseline alanine
aminotransferase (ALT) levels greater than 3 times the ULN
was similarly low for both treatment groups. No patient
experienced a postbaseline ALT level greater than 5 times
the ULN. One patient in group 2 had an aspartate amino-
transferase (AST) level greater than 5 times the ULN at a
single study visit, all subsequent values were normal.
Twelve weeks of treatment with these regimens normalized
liver enzyme levels in almost all patients with high baseline
liver enzyme levels: 96.9% (63 of 65) and 100% (66 of 66)
of group 1 and group 2 patients, respectively normalized
high baseline ATL levels after being treated; AST levels were
normalized in 98.4% (60 of 61) and 91.8% (56 of 61) of
group 1 and group 2 patients, respectively. Median changes
from baseline in aminotransferase values at the ﬁnal treat-
ment visit were similar when comparing treatment groups
(ALT, -35.0 vs -36.0 U/L; AST, -22.0 vs -21.0 U/L for group 1
and group 2, respectively).Discussion
PEARL-II examined an all-oral, interferon-free regimen
with or without RBV exclusively in pegIFN/RBV treatment-
experienced, noncirrhotic patients with HCV genotype 1b
infection. The intent-to-treat SVR12 rates of 96.6%–100% in
patients receiving the 12-week regimen of ABT-450/ritonavir/ombitasvir and dasabuvir with or without RBV,
respectively, were superior to the historical rate of
telaprevir plus pegIFN/RBV. The SVR12 rates of this mul-
titargeted regimen with RBV conﬁrm results of the phase 2b
AVIATOR study17 in prior null responders, the most difﬁ-
cult to cure of pegIFN/RBV nonresponders, and further
expands efﬁcacy conclusions to patients who were partial
responders and relapsers to pegIFN/RBV treatment. In
addition, PEARL-II showed the noninferiority of the RBV-
free regimen to the RBV-containing regimen, supporting
the use of ABT-450/ritonavir/ombitasvir and dasabuvir
without RBV for 12 weeks in the treatment of HCV geno-
type 1b–infected pegIFN/RBV-experienced patients without
cirrhosis.
The TEAEs associated with either group in this 12-week
regimen generally were mild and manageable. Overall, only
2 (1.1%) treated patients discontinued treatment because
of AEs, and the 5 serious TEAEs reported in 4 patients
were considered to be unrelated to study drug by the
investigators. As expected, known RBV AEs (fatigue, nausea,
insomnia, rash, anemia, and increased bilirubin level) were
statistically more prevalent in group 1, although the fre-
quency and severity appeared to be reduced compared with
when RBV was combined with pegIFN.7,18 Hemoglobin level
decreases also were more frequent in group 1 although few
(2.2%) reached clinical signiﬁcance, and AEs leading to RBV
dose reduction occurred in only 4 patients. Increased bili-
rubin levels in group 1 predominantly were caused by indi-
rect bilirubinemia, consistent with the hemolysis associated
with RBV and the known effect of ABT-450 on the bilirubin
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increases in group 2 suggest the predominant causewasRBV-
related hemolysis. Liver enzyme level normalization was
consistent with the high rate of virologic response.
The SVR12 rates reported here compare favorably with
published reports of other interferon-free regimens using
the NS5B RNA polymerase inhibitor sofosbuvir in combi-
nation with NS5A inhibitors (daclatasvir or ledipasvir), or
with an NS3/4A protease inhibitor (simeprevir). Combina-
tions of sofosbuvir plus daclatasvir with or without RBV
have shown 95% or greater SVR12 in 41 treatment-
experienced genotype 1 patients, of whom only 8 patients
were genotype 1b.19 Similar SVR12 rates have been re-
ported in treatment-experienced genotype 1 patients with
sofosbuvir plus ledipasvir with (21 of 21; 100%) or without
(18 of 19; 95%) RBV, although only 6 genotype 1b patients
were included.20 In 13 genotype 1b–infected patients
receiving the combination of simeprevir plus sofosbuvir
with or without RBV, 100% SVR8 was reported.21 A larger
study of daclatasvir in combination with asunaprevir in
pegIFN/RBV treatment-experienced genotype 1b–infected
patients showed SVR12 rates of 80% (70 of 87) with
patients not achieving an SVR primarily owing to a lack of
efﬁcacy and AEs.22 Together with the results from PEARL-II,
these data support a multitargeted approach to achieve SVR.
Additionally, PEARL-II assessed efﬁcacy exclusively in 179
genotype 1b-infected patients and was powered to analyze
the contribution of RBV in treatment-experienced patients.
One of the strengths of the PEARL-II study includes its
large sample size in genotype 1b–infected patients, the most
prevalent subgenotype worldwide, including patients with
previous null response and relapse to pegIFN/RBV treat-
ment. Treatment-experienced genotype 1b–infected patients
have not been studied extensively with currently approved
or investigational IFN-free regimens, hence this large patient
population represents a group with unmet need. Study lim-
itations include the open-label study design; the exclusion of
patients with cirrhosis, hepatitis B virus, or human immu-
nodeﬁciency virus co-infection; and that these ﬁndings may
be speciﬁc to genotype 1b–infected patients. However, the
efﬁcacy and safety of this regimen recently was described
from phase 3 studies in treatment-naive patients infected
with genotype 1a and 1b,23 and in patients with cirrhosis.24
In conclusion, a 12-week regimen of ABT 450/ritonavir/
ombitasvir and dasabuvir with or without RBV generally
was well tolerated in pegIFN/RBV treatment-experienced,
noncirrhotic, HCV genotype 1b–infected adults, as evi-
denced by the low rate of treatment discontinuation and
serious AEs. In addition, the regimen without RBV was
associated with fewer AEs of fatigue, nausea, insomnia, rash,
and a lower rate of laboratory abnormalities including
bilirubin level increase and hemoglobin level decrease. SVR
rates of 96.6% and 100% were achieved, including 93.5%
and 100% in the difﬁcult-to-treat previous pegIFN/RBV null
responders, with or without RBV, respectively. Therefore,
ABT-450/ritonavir/ombitasvir and dasabuvir without RBV
is sufﬁcient to achieve optimal treatment of HCV genotype
1b infection in this population.Supplementary Material
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